Active Ingredient History
Silibinin (INN), also known as silybin (both from Silybum, the generic name of the plant from which it is extracted), is the major active constituent of silymarin, a standardized extract of the milk thistle, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silychristin, silidianin, and others. Silibinin itself is a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio. Silibinin is used in pure forms as a medication, and more frequently as an active ingredient in milk thistle–derived herbal supplements. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acute-On-Chronic Liver Failure (Phase 4)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Depression (Phase 3)
Diabetic Nephropathies (Phase 2)
Healthy Volunteers (Phase 1)
Hepatitis C (Phase 2)
Hepatitis C, Chronic (Phase 2/Phase 3)
HIV (Phase 2)
Hypertension (Phase 4)
Inflammation ()
Ischemic Stroke (Phase 2)
Liver Cirrhosis (Phase 3)
Liver Failure (Phase 3)
Mushroom Poisoning (Phase 2/Phase 3)
Oxidative Stress (Phase 2)
Prostatic Neoplasms (Phase 2)
Proteinuria (Phase 2)
Smoking (Phase 1)
Work (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue